Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Capital Leases (2019 - 2025)

Historic Capital Leases for Marimed (MRMD) over the last 7 years, with Q3 2025 value amounting to $2.2 million.

  • Marimed's Capital Leases fell 294.77% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 294.77%. This contributed to the annual value of $1.9 million for FY2024, which is 1000.0% down from last year.
  • As of Q3 2025, Marimed's Capital Leases stood at $2.2 million, which was down 294.77% from $2.2 million recorded in Q2 2025.
  • Marimed's Capital Leases' 5-year high stood at $2.7 million during Q2 2024, with a 5-year trough of $22000.0 in Q4 2021.
  • Over the past 5 years, Marimed's median Capital Leases value was $1.5 million (recorded in 2023), while the average stood at $1.2 million.
  • Its Capital Leases has fluctuated over the past 5 years, first plummeted by 5055.07% in 2021, then soared by 199545.45% in 2022.
  • Quarter analysis of 5 years shows Marimed's Capital Leases stood at $22000.0 in 2021, then skyrocketed by 1995.45% to $461000.0 in 2022, then skyrocketed by 364.21% to $2.1 million in 2023, then dropped by 10.0% to $1.9 million in 2024, then grew by 12.82% to $2.2 million in 2025.
  • Its Capital Leases was $2.2 million in Q3 2025, compared to $2.2 million in Q2 2025 and $1.9 million in Q1 2025.